Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Milton S. Hershey Medical Center
With
Biliary Tract Carcinoma (BTC) is a leading cause of cancer-related mortality. The newly developed small molecule inhibitor of cyclin-dependent kinases (CDK4 and CDK6), abemaciclib, provides a new opportunity of treating patients with BTC. The goal of this clinical study is to determine the efficacy and safety of abemaciclib in patients with advanced or metastatic BTC that has progressed or intolerant to one or more lines of systemic therapy, or treatment-naïve subjects who either decline or being considered not a good candidate first-line systemic chemotherapy per the opinion of the treating physician. The investigator's objectives for this study are as follows: Primary Objectives: • To estimate the objective response rate (ORR) Secondary Objectives: * To determine progression free survival (PFS) * To determine the disease control rate (DCR) * To determine the overall survival (OS) rate at 6 and 12 months * To determine quality of life (QoL) using EORTC-QLQ-C30
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted